Cargando…

Improving the Effects of Imeglimin on Endothelial Function: A Prospective, Single-Center, Observational Study

INTRODUCTION: Endothelial dysfunction is a risk factor for cardiovascular disease in patients with diabetes. We hypothesized that imeglimin, a novel oral hypoglycemic agent, would improve endothelial function. METHODS: In this study, imeglimin was administered to patients with type 2 diabetes and Hb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uchida, Taisuke, Ueno, Hiroaki, Konagata, Ayaka, Taniguchi, Norifumi, Kogo, Fumiko, Nagatomo, Yuma, Shimizu, Koichiro, Yamaguchi, Hideki, Shimoda, Kazuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981829/ https://www.ncbi.nlm.nih.gov/pubmed/36732433 http://dx.doi.org/10.1007/s13300-023-01370-z

Ejemplares similares

A Response to Letter to the Editor: Can Imeglimin Improve the Systolic Time Intervals in Diabetes Mellitus?
por: Uchida, Taisuke, et al.
Publicado: (2023)

Association between personality traits and glycemic control after inpatient diabetes education
por: Uchida, Taisuke, et al.
Publicado: (2023)

Stimulatory effect of imeglimin on incretin secretion
por: Yingyue, Quan, et al.
Publicado: (2023)

Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects
por: Fouqueray, Pascale, et al.
Publicado: (2022)

Letter to the Editor: Can Imeglimin Improve the Systolic Time Intervals in Diabetes Mellitus?
por: Nishikawa, Tomoaki, et al.
Publicado: (2023)

Longitudinal changes in an autonomously functioning thyroid nodule with coexisting follicular thyroid carcinoma over 14 years
por: Uchida, Taisuke, et al.
Publicado: (2022)

Molecular Mechanisms by Which Imeglimin Improves Glucose Homeostasis
por: Yaribeygi, Habib, et al.
Publicado: (2020)

Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin
por: Theurey, Pierre, et al.
Publicado: (2022)

Effects of the anti-diabetic imeglimin in hyperglycemic mice with septic shock
por: Wagner, F, et al.
Publicado: (2012)

The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells
por: Vial, Guillaume, et al.
Publicado: (2021)

Imeglimin‐mediated glycemic control in maternally inherited deafness and diabetes
por: Ishibashi, Ryoichi, et al.
Publicado: (2023)

Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration
por: Detaille, D, et al.
Publicado: (2016)

The Effects of Imeglimin on the Daily Glycemic Profile Evaluated by Intermittently Scanned Continuous Glucose Monitoring: Retrospective, Single-Center, Observational Study
por: Oda, Tomoyasu, et al.
Publicado: (2022)

Imeglimin exerts favorable effects on pancreatic β-cells by improving morphology in mitochondria and increasing the number of insulin granules
por: Sanada, Junpei, et al.
Publicado: (2022)

Effects of imeglimin on mitochondrial function, AMPK activity, and gene expression in hepatocytes
por: Hozumi, Kaori, et al.
Publicado: (2023)

Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes
por: Vuylsteke, Valerie, et al.
Publicado: (2015)

Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes
por: Hallakou‐Bozec, Sophie, et al.
Publicado: (2020)

Glucose-Lowering Effects of Imeglimin and Its Possible Beneficial Effects on Diabetic Complications
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

Development of Imeglimin Electrospun Nanofibers as a Potential Buccal Antidiabetic Therapeutic Approach
por: Alamer, Ali A., et al.
Publicado: (2023)

Imeglimin preserves islet β‐cell mass in Type 2 diabetic ZDF rats
por: Hallakou‐Bozec, Sophie, et al.
Publicado: (2020)

Current understanding of imeglimin action on pancreatic β‐cells: Involvement of mitochondria and endoplasmic reticulum homeostasis
por: Fauzi, Muhammad, et al.
Publicado: (2022)

Potential Ketoacidosis Linked to Imeglimin and Metformin Co-administration in a Patient With Type 2 Diabetes
por: Yamagishi, Hirofumi, et al.
Publicado: (2023)

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
por: Fouqueray, Pascale, et al.
Publicado: (2013)

Short‐and long‐term administration of imeglimin counters cardiorenal dysfunction in a rat model of metabolic syndrome
por: Lachaux, Marianne, et al.
Publicado: (2020)

A novel mechanism of imeglimin‐mediated insulin secretion via the cADPR‐TRP channel pathway
por: Funazaki, Shunsuke, et al.
Publicado: (2021)

Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity
por: Theurey, Pierre, et al.
Publicado: (2022)

Current status of diabetes treatment in Miyazaki Prefecture, Japan: Results of a questionnaire survey conducted in 2016 and 2020
por: Uehira, Yudai, et al.
Publicado: (2022)

Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action
por: Hallakou-Bozec, Sophie, et al.
Publicado: (2021)

Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes
por: Tomita, Yoshiko, et al.
Publicado: (2022)

Suppression of murine tumour growth through CD8(+) cytotoxic T lymphocytes via activated DEC‐205(+) dendritic cells by sequential administration of α‐galactosylceramide in vivo
por: Kogo, Hideki, et al.
Publicado: (2017)

Efficacy, safety and tolerability of imeglimin in patients with type 2 diabetes mellitus: A meta‐analysis of randomized controlled trials
por: Hagi, Katsuhiko, et al.
Publicado: (2023)

Single-port laparoscopic-assisted resection for a large abdominal cystic lymphangioma: a case report
por: Kogo, Hideki, et al.
Publicado: (2018)

Successful abdominal wound closure for treatment of severe peritonitis using negative pressure wound therapy with continuous mesh fascial traction: a case report
por: Kogo, Hideki, et al.
Publicado: (2018)

Preservation effect of imeglimin on pancreatic β-cell mass: Noninvasive evaluation using (111)In-exendin-4 SPECT/CT imaging and the perspective of mitochondrial involvements
por: Fauzi, Muhammad, et al.
Publicado: (2022)

Adropin Contributes to Anti-Atherosclerosis by Suppressing Monocyte-Endothelial Cell Adhesion and Smooth Muscle Cell Proliferation
por: Sato, Kengo, et al.
Publicado: (2018)

Concurrent Use of Teneligliptin and Canagliflozin Improves Glycemic Control with Beneficial Effects on Plasma Glucagon and Glucagon-Like Peptide-1: A Single-Arm Study
por: Noda, Tomoho, et al.
Publicado: (2019)

Fulminant hepatitis and elevated levels of sIL-2R in thyroid storm
por: Tanaka, Yuri, et al.
Publicado: (2019)

Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24‐week, randomized, double‐blind, placebo‐controlled, dose‐ranging phase 2b trial
por: Dubourg, Julie, et al.
Publicado: (2021)

Effect of patient characteristics on the efficacy and safety of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus: A post‐hoc analysis of two randomized, placebo‐controlled trials
por: Hagi, Katsuhiko, et al.
Publicado: (2023)

Oxygen Concentration-Dependent Oxidative Stress Levels in Rats
por: Nagatomo, Fumiko, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_9hakqp85iu1sq071jqf2v8v1no